NDAORALTABLET
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORETICYL FORTE is a fixed-dose oral combination tablet containing deserpidine (a Rauwolfia alkaloid antihypertensive) and hydrochlorothiazide (a thiazide diuretic), approved in 1959 for hypertension management. The combination leverages dual mechanisms: deserpidine depletes catecholamine stores while hydrochlorothiazide reduces sodium reabsorption and blood volume. This product targets patients with moderate to severe hypertension requiring combination therapy.
LOE Approaching
Product is in late-stage lifecycle with minimal linked career opportunities, suggesting a small or legacy-focused team managing declining volumes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect ORETICYL FORTE's legacy status and minimal active career pipeline at AbbVie. Roles on this product would primarily involve managing a declining brand through its final commercial stages rather than launching or growing a new therapy.
Brand ManagerField Sales Representative
Worked on ORETICYL FORTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.